VCYT Veracyte, Inc.
$45.03
Platform & Compounding FCF 85%
Two-stage FCF DCF
Mild · Conviction

Fair Value

Trading 1.4% below fair value

You pay $45.03
Bear $28.54
Fair $45.66
Bull $66.25
Bear $28.54 -36.6% 11% stage 1 growth, 12% discount
Fair $45.66 +1.4% 18% stage 1 growth, 12% discount
Bull $66.25 +47.1% 24% stage 1 growth, 12% discount

Key Value Driver

FCF growth rate (18% base case)

Terminal Value % of EV 41%
Implied Market Multiple 34.3x

Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $45.25 from 20 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $45.66 per share.

Warnings

Stock-based employee pay equals 66% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions